HomeSGEN • BMV
add
Seagen
Previous close
$3,711.48
Year range
$3,711.48 - $3,711.48
Market cap
43.15B USD
P/E ratio
-
Dividend yield
-
Market news
Financials
Income Statement
Revenue
Net income
(USD) | Sep 2023info | Y/Y change |
---|---|---|
Revenue | 648.65M | 27.11% |
Operating expense | 262.69M | 24.86% |
Net income | -215.79M | -13.09% |
Net profit margin | -33.27 | 11.02% |
Earnings per share | -1.15 | -11.65% |
EBITDA | -209.33M | -19.47% |
Effective tax rate | 0.26% | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Sep 2023info | Y/Y change |
---|---|---|
Cash and short-term investments | 1.24B | -29.86% |
Total assets | 3.63B | 0.42% |
Total liabilities | 1.08B | 35.94% |
Total equity | 2.55B | — |
Shares outstanding | 188.66M | — |
Price to book | 274.52 | — |
Return on assets | -16.01% | — |
Return on capital | -21.12% | — |
Cash Flow
Net change in cash
(USD) | Sep 2023info | Y/Y change |
---|---|---|
Net income | -215.79M | -13.09% |
Cash from operations | -35.82M | 58.21% |
Cash from investing | 142.49M | 119.31% |
Cash from financing | 15.52M | -15.59% |
Net change in cash | 119.90M | 1,958.05% |
Free cash flow | 71.52M | 1,141.10% |
About
Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington, is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.
The company's flagship product Adcetris is commercially available for four indications in more than 65 countries, including the U.S., Canada, Japan and members of the European Union.
To expand on the clinical opportunities of brentuximab vedotin, Seattle Genetics is conducting a broad clinical development program
to evaluate its therapeutic potential in earlier lines of its approved indications as well as in a range of other lymphoma and non-lymphoma settings. The company is jointly developing brentuximab vedotin in collaboration with Takeda Pharmaceutical Company. Wikipedia
Founded
Jul 15, 1997
Headquarters
Website
Employees
3,256